Author

Jeremy Chien

University of California Davis Medical CenterORCID 0000-0003-4744-8374Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Assay:DNA methylation· 1 Research Focus:drug response / drug discovery· 1 Assay:proteomics· 1 Research Focus:variant calling· 1

Frequent Co-Authors

Ann L. ObergiD· 1 shared Anya Zhao· 1 shared Jamie Nadine Bakkum-GameziD· 1 shared Jamison L. VanBlaricom· 1 shared John Weroha· 1 shared Julie K. StaubiD· 1 shared Kay Minn· 1 shared Ling Jin· 1 shared

Activity by Year

2018-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Ann L. ObergORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologyCell Communication and SignalingPeer-reviewedAug 28, 2026

Drug-induced nuclear cathepsin L (nCTSL) defines a targetable DNA damage response axis and PARP inhibitor sensitivity in ovarian cancer

Prabhu Thirusangu, Ling Jin, Shruti Rao…·Viji Shridhar

This study identifies nuclear cathepsin L (nCTSL) as a biomarker for PARP inhibitor sensitivity in ovarian cancer and shows that combining clofarabine with PARP inhibitors enhances therapeutic response.

1 citation

humanproteomics

𝕏 PostBluesky

Cancer BiologybioRxivPreprintJul 31, 2018

Heterozygous mutations in p97 and resistance to p97 inhibitors

Prabhakar Bastola, Kay Minn, Jeremy Chien

The paper identifies a heterozygous frameshift mutation in p97 in HCT116 cells and shows that resistance to p97 inhibitors can arise from a missense mutation in the non-mutated allele.

DOI 10.1101/380964

humanDNA methylation

𝕏 PostBluesky